Ex vivo expansion of CD4+CD25+ T regulatory cells for immunosuppressive therapy

Cytometry Part A

Volumn 75, Issue 3, 2009, Pages 175-188

  Trzonkowski, Piotr ^a   Szaryńska, Magdalena ^a   Myśliwska, Jolanta ^a   Myśliwski, Andrzej ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Adoptive therapy; CD4+CD25+ T regulatory cells; Cellular therapy; Humans; Immunosuppression

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CALCINEURIN INHIBITOR; CALCITRIOL; COLECALCIFEROL; CYCLOPHOSPHAMIDE; ESTROGEN; FLUDARABINE; GLUCOCORTICOID; INTERLEUKIN 2; RAPAMYCIN; RETINOIC ACID; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR;

CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CELL SELECTION; CELL THERAPY; DENDRITIC CELL; FLOW CYTOMETRY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW;

ADOPTIVE TRANSFER; ANIMALS; AUTOIMMUNE DISEASES; HUMANS; IMMUNOSUPPRESSION; T-LYMPHOCYTES, REGULATORY;

EID: 65349184459     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.20659     Document Type: Review

References (191)

1. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003;3:199-210.
2. Owen RD. Immunogenetic consequences of vascular anastomoses between bovine twins. Science 1945;102:400-401.
3. Billingham RE, Brent L, Medawar PB. Activity acquired tolerance of foreign cells. Nature 1953;172:603-606.
4. Gershon RK, Kondo K. Infectious immunological tolerance. Immunology 1971; 21:903-914.
5. Gershon RK, Kondo K. Cell interactions in the induction of tolerance: The role of thymic lymphocytes. Immunology 1970;18:723-737.
6. Fujimoto S, Greene M, Sehon AH. Immunosuppressor T cells in tumour bearing host. Immunol Commun 1975;4:201-217.
7. North RJ, Bursuker I. Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1 + 2-suppressor T cells downregulate the generation of Ly-1-2 + effector Tcells. J Exp Med 1984;159:1295-1311.
8. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-1164.
9. Sansom DM, Walker LS. The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4)in regulatoryT-cell biology. Immunol Rev 2006;212:131-148.
10. Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, Mak TW, Saka- guchi S. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000;192:303-310.
11. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998;188:287-296.
12. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol 2007;8:1353-1362.
13. Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity2004;21:589-601.
14. Gondek DC, Lu LF, Quezada SA, Sakaguchi S, Noelle RJ. Cutting edge: Contact- mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol 2005;174:1783-1786.
15. Taams LS, van Amelsfort JM, Tiemessen MM, Jacobs KM, de Jong EC, Akbar AN, Bijlsma JW, Lafeber FP. Modulation of monocyte/macrophage function by human CD4+CD25+ regulatoryT cells. Hum Immunol 2005;66:222-230.
16. Piccirillo CA, Shevach EM. Control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 2001;167:1137-1140.
17. Trzonkowski P, Szmit E, Mysliwska J, Dobyszuk A, Mysliwski A. CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction. Clin Immunol 2004;112:258-267.
18. Lewkowicz P, Lewkowicz N, SasiakA, Tchorzewski H. Lipopolysaccharide- activated CD4+CD25+ Tregulatorycells inhibit neutrophil function and promote their apo- ptosis and death. J Immunol 2006;177:7155-7163.
19. Suri-Payer E, Amar AZ, Thornton AM, Shevach EM. CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage ofimmunoregulatorycells. J Immunol 1998;160:1212-1218.
20. Wu J, Yi S, Ouyang L, Jimenez E, Simond D, Wang W, Wang Y, Hawthorne WJ, O'Connell PJ. In vitro expanded human CD4+CD25+ regulatory T cells are potent suppressors of T-cell-mediated xenogeneic responses. Transplantation 2008;85: 1841-1848.
21. Waldmann H, Chen TC, Graca L, Adams E, Daley S, Cobbold S, Fairchild PJ. Regulatory T cells in transplantation. Semin Immunol 2006;18:111-119.
22. Karim M, Feng G, Wood KJ, Bushell AR. CD25+CD4+ regulatory T cells generated by exposure to a model protein antigen prevent allograft rejection: Antigen-specific reactivation in vivo is critical for bystander regulation. Blood 2005;105:4871-4877.
23. Pacholczyk R, Kern J, Singh N, Iwashima M, Kraj P, Ignatowicz L. Nonself-antigens are the cognate specificities of Foxp3+ regulatory T cells. Immunity 2007;27:493-504.
24. Kasow KA, Chen X, Knowles J, Wichlan D, Handgretinger R, Riberdy JM. Human CD4+CD25+ regulatory T cells share equally complex and comparable repertoires with CD4+CD25- counterparts. J Immunol 2004;172:6123-6128.
25. Karim M, Kingsley CI, Bushell AR, Sawitzki BS, Wood KJ. Alloantigen-induced CD25+CD4+ regulatory T cells can develop in vivo from CD25-CD4+ precursors in a thymus-independent process. J Immunol 2004;172:923-928.
26. Hafler DA, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Fukaura H. Oral administration of myelin induces antigen-specific TGF-β1 secreting T cells in patients with multiple sclerosis. Ann N YAcad Sci 1997;835:120-131.
27. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389:737-742.
28. Collison LW, Workman CJ, Kuo TT, BoydK, WangY, VignaliKM, Cross R, SehyD, Blumberg RS, Vignali DA. The inhibitory cytokine IL-35 contributes to regulatory T-cellfunction.Nature2007;450:566-569.
29. Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, McInnes IB, Liew FY. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 2007;37:3021-3029.
30. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, Hopner S, Centonze D, Bernardi G, Dell'Acqua ML, Rossini PM, Battistini L, Rotzschke O, Falk K. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: Hydrolysis ofextracellular ATP and immune suppression. Blood 2007;110:1225-1232.
31. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjyoji K, Linden J, Oukka M, Kuchroo VK, Strom TB, Robson SC. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007;204:1257-265.
32. Bopp T, Becker C, Klein M, Klein-Hessling S, Palmetshofer A, Serfling E, Heib V, Becker M, Kubach J, Schmitt S, Stoll S, Schild H, Staege MS, Stassen M, Jonuleit H, Schmitt E. Cyclic adenosine monophosphate is a key component of regulatory T cell-mediatedsuppression.JExpMed2007;204:1303-1310.
33. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25high regulatory cells in human peripheralblood. J Immunol2001;167:1245-1253.
34. Peters JH, Hilbrands LB, Koenen HJ, Joosten I. Ex vivo generation of human alloan- tigen-specific regulatory T cells from CD4(pos)CD25(high) T cells for immunotherapy. PLoS ONE 2008;3:e2233.
35. Hoffmann P, Boeld TJ, Eder R, Albrecht J, Doser K, Piseshka B, Dada A, Niemand C, Assenmacher M, Orsó E, Andreesen R, Holler E, Edinger M. Isolation of CD4+CD25+ regulatory T cells for clinical trials. Biol Blood Marrow Transplant. 2008;12:267-274.
36. Taams LS, Smith J, Rustin MH, Salmon M, Poulter LW, Akbar AN. Human anergic/ suppressive CD4(+)CD25(+) T cells: A highly differentiated and apoptosis-prone population. Eur J Immunol2001;31:1122-1131.
37. Taams LS, Vukmanovic-Stejic M, Smith J, Dunne PJ, Fletcher JM, Plunkett FJ, Ebel- ing SB, Lombardi G, Rustin MH, Bijlsma JW, Lafeber FP, Salmon M, Akbar AN. Antigen-specific T cell suppression by human CD4+CD25+ regulatory T cells. Eur J Immunol 2002;32:1621-1630.
38. Tang Q,BluestoneJA. Regulatory T-cellphysiology and application to treat autoimmunity. ImmunolRev2006;212:217-237.
39. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-1061.
40. Trzonkowski P, Zaucha JM, Mysliwska J, Balon J, Szmit E, Halaburda K, Bienias- zewska M, Mlotkowska M, Hellmann A, Mysliwski A. Differences in kinetics of donor lymphoid cells in response to G-CSF administration may affect the incidence and severity of acute GvHD in respective HLA-identical sibling recipients. Med Oncol 2004;21:81-94.
41. Hoffmann P, Eder R, Kunz-Schughart LA, Andreesen R, Edinger M. Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. Blood 2004;104:895-903.
42. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 2001;193:1303-1310.
43. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ Treg cells. J Exp Med 2006;203:1701-1711.
44. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, Solomon M, Selby W, Alexander SI, Nanan R, Kelleher A, Fazekas de St Groth B. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated Tcells. J Exp Med 2006;203:1693-1700.
45. Fu S, Yopp AC, Mao X, Chen D, Zhang N, Chen D, Mao M, Ding Y, Bromberg JS. CD4+ CD25+ CD62+ T-regulatory cell subset has optimal suppressive and proliferative potential. Am J Transplant 2004;4:65-78.
46. Valmori D, Merlo A, Souleimanian NE, Hesdorffer CS, Ayyoub M. A peripheral circulating compartment of natural naive CD4 Tregs.J Clin Invest 2005;115:1953-1962.
47. Hoffmann P, Eder R, Boeld TJ, Doser K, Piseshka B, Andreesen R, Edinger M. Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion.Blood 2006;108:4260-4267.
48. Koenen H,Fasse E,Joosten I. CD27/CFSE-based ex vivo selection of highly suppressive alloantigen-specific human regulatory T cells. J Immunol 2005;174:7573-7583.
49. Coenen JJ, Koenen HJ, van Rijssen E, Hilbrands LB, Joosten I. Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood 2006;107:1018-1023.
50. Read S, Malmstrom V, Powrie F. CTLA4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation. J Exp Med 2000;192:295-302.
51. Trzonkowski P, Szmit E, Mysliwska J, Mysliwski A. CD4+CD25+ Tregulatory cells inhibit cytotoxic activity of CTL and NK cells in humans-impact of immunosenescence. Clin Immunol 2006;119:307-316.
52. Mizobuchi T, Yasufuku K, Zheng Y, Haque MA, Heidler KM, Woods K, Smith GN, Cummings OW, Fujisawa T, Blum JS, Wilkes DS. Differential expression of Smad7 transcipts identifies the CD4+CD25+CD45RChigh regulatory T cells that mediate type V collagen-induced tolerance to lung allografts. J Immunol2003;171:1140-1147.
53. Strickland DH, Stumbles PA, Zosky GR, Subrata LS, Thomas JA, Turner DJ, Sly PD,Holt PG. Reversal of airway hyperresponsiveness by induction of airway mucosal CD4+CD25+ regulatory T cells. J Exp Med 2006;203:2649-2660.
54. Stassen M, Fondel S, Bopp T, Richter C, Muller C, Kubach J, Becker C, Knop J, Enk AH, Schmitt S, Schmitt E, Jonuleit H. Human CD25+ regulatory T cells: Two subsets defined by the integrins α4 β7or α4 β1 confer distinct suppressive properties upon CD4+ T helper cells. Eur J Immunol 2004;34:1303-1311.
55. Marski M, Kandula S, Turner JR, Abraham C. CD18 is required for optimal development and function of CD4+CD25+ Tregulatory cells. J Immunol 2005;175:7889-7897.
56. Ji J, Masterson J, Sun J, Soong L. CD4+CD25+ regulatory T cells restrain pathogenic responses during Leishmania amazonesis infection. J Immunol 2005;174:7147-7153.
57. Zheng Y, Manzotti M, Liu M, Burke F, Mead KI, Sansom DM. CD86 and Cd80 differentially modulate the suppressive function of human Tregs. J Immunol 2004; 172:2778-2784.
58. Fritzsching B, Oberle N, Eberhardt N, Quick S, Haas J, Wildemann B, Krammer PH, Suri-Payer E. In contrast to effector cells, CD4+CD25+FoxP3 + regulatory T cells are highly susceptible to CD95 ligand - but not TCR mediated cell death. J Immunol2005;175:32-36.
59. Zhao DM, Thornton AM, DiPaolo RJ, Shevach EM. Activated CD4+CD25+ T cells selectivelykill B lymphocytes. Blood 2006;107:3925-3932.
60. Venet F, Pachot A, Debart Al, Bohe J, Bienvenu J, Lepape A, Powell WS, Moneret G. Human CD4+CD25+ regulatory T lymphocytes inhibit LPS induced monocyte survival through Fas/FasL dependent mechanism. J Immunol 2006;177:6540-6547.
61. Soper DM, Kasprowicz DJ, Ziegler SF. IL2R-/ links IL2R signaling with FoxP3 expression. Eur J Immunol 2007;37:1817-1826.
62. Sanchez J, Casano J, Alvarez MA, Roman-Gomez J, Martin C, Martinez F, Gomez P, Serrano J, Herrera C, Torres A. Kinetic of regulatory CD25high and activated CD134+ (OX40+) T lymphocytes during acute and chronic GVHD after allogeneic bone marrow transplantation. Br J Haematol 2004;126:697-703.
63. Choi BK, Bae JS, Choi EM, Kang WJ, Sakaguchi S, Vinay DS, Kwon BS. 4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells. J Leukoc biol 2004;75:785-791.
64. McHugh, RS Whitters MJ, Piccirillo CA, Young DA, Shevach EM, Collins M, Byrne MC. CD4+CD25+ immunoregulatory T cells: Gene expression analysis reveals a functional role for GITR. Immunity 2002;16:311-323.
65. Jarvien IZ, Blazar BR, Adei OA, Strom TB, Noelle RJ. CD154 on the surface of CD4+CD25+ regulatory T cells contributes to skin transplant tolerance. Transplantation 2003;76:1375-1379.
66. van Maurik A, Herber M, Wood KJ, Jones ND. CD4+CD25+ alloantigen specific immunoregulatory cells that can prevent CD8+ T cell mediated graft rejection: Implications for anti-CD154 immunothrapy. J Immunol 2002;169:5401-5404.
67. Ghiringhelli F, Menard C, Terme M, Flament C, Taieb J, Chaput N, Puig PE, Novault S, Escudier B, Vivier E, Lecesne A, Robert C, Blay JY, Bernard J, Caillat-Zucman S, Freitas A, Tursz T, Wagner-Ballon O, Capron C, Vainchencker W, Martin F, Zitvogel L. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner. J Exp Med 2005;202:1075-1085.
68. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatoryTcells that control autoimmune diabetes. Immunity2000;12:431- 440.
69. Tai X, Cowan M, Feigenbaum L, Singer A. CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independ- entlyofinterleukin 2. Nat Immunol2005;6:152-162.
70. Habicht A, Shirine D, Jurewicz M, Fife BT, Yagita H, Azuma M, Sayegh M, Guleria I. A link between PDL1 and T regulatory cells in fetomaternal tolerance J Immunol 2007;179:5211-5219.
71. Caramalho I, Lopes-Carvalho T, Ostler D, Zelenay S, Haury M, Demengeot J. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med 2003;197:403-411.
72. Bruder D, Probst-Kepper M, Westendorf AM, Geffers R, Beissert S, Loser K, von BoehmerH, BuerJ, HansenW. Neuropilin-1: A surface marker of regulatory T cells. Eur J Immunol 2004;34:623-630.
73. Iellem A, Mariani M, Lang R, Recalde H, Panina-Bordignon P, Sinigaglia F, D'Ambrosio D. Unique chemotactic response profile and specific expression of che- mokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med 2001;194:847-853.
74. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdernon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon L, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-949.
75. Ardalan MR, Maljaei H, Shoja MM, Piri AR, Khosroshahi HT, Noshad H, Argani H. Calcitriol started in the donor, expands the population of CD4+CD25+ T cells in renal transplant recipients. Transplant Proc 2007;39:951-953.
76. Game DS, Hernandez-Fuentes MP, Lechler RI. Everolimus and basiliximab permit suppression by human CD4+CD25+cellsin vitro. Am J Transplant2005;5:454- 464.
77. Trzonkowski P, Zilvetti M, Chapman S, Wieckiewicz J, Sutherland A, Friend P, Wood KJ. Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab- depleted kidney transplant recipients treated with reduced immunosuppression. Am J Transplant 2008;8:338-347.
78. Basu S, Golovina T, Mikheeva T, June CH, Riley JL. Cutting edge: Foxp3-mediated induction of pim 2 allows human Tregulatory cells to preferentially expand in rapamycin. J Immunol 2008;180:5794-5798.
79. Segundo DS, Ruiz JC, Izquierdo M, Fernández-Fresnedo G, GtJmez-Alamillo C, Merino R, Benito MJ, Cacho E, Rodrigo E, Palomar R, LtJpez-Hoyos M, Arias M. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients. Transplantation 2006;82:550-557.
80. Zeiser R, Nguyen VH, Beilhack A, Buess M, Schulz S, Baker J, Contag CH, Negrin RS. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006;108:390-399.
81. Suárez A, López P, Gómez J, Gutiérrez C. Enrichment of CD4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorti- coids. Ann Rheum Dis 2006;65:1512-1517.
82. Chen X, Oppenheim JJ, Winkler-Pickett RT, Ortaldo JR, Howard OM. Glucocorticoid amplifies IL-2-dependent expansion of functional FoxP3(+)CD4(+)CD25(+) T regulatory cells in vivo and enhances their capacity to suppress EAE. Eur J Immunol 2006;36:2139-2149.
83. Kreijveld E, Koenen HJ, Klasen IS, Hilbrands LB, Joosten I. Following anti-CD25 treatment, a functional CD4+CD25+ regulatory T-cell pool is present in renal transplant recipients. Am J Transplant 2007;7:249-255.
84. Watanabe T, Masuyama J, Sohma Y, Inazawa H, Horie K, Kojima K CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T-cells. Clin Immunol 2006;120:247-259.
85. Ciancio G, Burke GW, Gaynor JJ, Carreno MR, Cirocco RE, Mathew JM. A randomized trial of three renal transplant induction antibodies: Early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005;80:457-465.
86. Lopez M, Clarkson MR, Albin M, Sayegh MH, Najafian N. A novel mechanism of action for anti-thymocyte globulin: Induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol 2006;17:2844-2853.
87. Feng X, Kajigaya S, Solomou EE, Keyvanfar K, Xu X, Raghavachari N, Munson PJ, Herndon TM, Chen J, Young NS. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. Blood 2008;111:3675-3683.
88. Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, Lipsky PE. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 2006;108:253-261.
89. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J Exp Med 2004;200:277-285.
90. Malek TR. The main function of IL-2 is to promote the development of T regulatory cells. J Leukoc Biol 2003;74:961-965.
91. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauf- fert B, Solary E, Bonnotte B, Martin F. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004;34:336-344.
92. BeyerM, KochanekM, Darabi K, PopovA, Jensen M, EndlE, Knolle PA, Thomas RK, von Bergwelt-Baildon M, Debey S, Hallek M, Schultze JL. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemiaafter therapywith fludarabine. Blood 2005;106:2018-2025.
93. Polanczyk MJ, Hopke C, Vandenbark AA, Offner H. Estrogen-mediated immuno- modulation involves reduced activation of effector T cells, potentiation of Treg cells, and enhanced expression of the PD-1 costimulatory pathway. J Neurosci Res 2006;84:370-378.
94. Polanczyk MJ, Hopke C, Huan J, Vandenbark AA, Offner H. Enhanced FoxP3 expression and Treg cell function in pregnant and estrogen-treated mice. J Neuroimmunol 2005;170:85-92.
95. Benson MJ, Pino-Lagos K, Rosemblatt M, Noelle RJ. All-trans retinoic acid mediates enhanced Treg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J Exp Med 2007;204:1765-1774.
96. Cozzo C, Larkin J III, Caton AJ. Cutting edge: Self-peptides drive the peripheral expansion of CD4+CD25+ regulatory T cells. J Immunol 2003;171:5678-5682.
97. Houtz B, Trotter J, Sasaki D. Tips on cell preparation for flow cytometric analysis and sorting. BD facsserivce technote 2004;9:1-4.
98. Gottenberg JE, Lavie F, Abbed K, Gasnault J, Le Nevot E, Delfraissy JF, Taoufik Y, Mariette X. CD4 CD25high regulatory T cells are not impaired in patients with primary Sjogren's syndrome. J Autoimmun 200524:235-242.
99. Cao D, van Vollenhoven R, Klareskog L, Trollmo C, MalmstromV. CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res Ther 2004;6:R335-R346.
100. Godfrey WR, Ge YG, Spoden DJ, Levine BL, June CH, Blazar BR, Porter SB. In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood 2004;104:453-456.
101. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002;99:3493-3499.
102. Lin CH, Hunig T. Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist. Eur J Immunol 2003;33:626-638.
103. Beyersdorf N, Balbach K, Hünig T, Kerkau T. Large-scale expansion of rat CD4+ CD25+ T(reg) cells in the absence of T-cell receptor stimulation. Immunology 2006;119:441-450.
104. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N. Cytokine storm in a phase 1 trial ofthe anti-CD28 monoclonal antibodyTGN 1412.N Engl J Med 2006;355:1018-1028.
105. Masuyama J, Kaga S, Kano S, Minota S. A novel costimulation pathway via the 4C8 antigen for the induction of CD4+ regulatory T cells. J Immunol 2002;169:3710-3716.
106. Choi BK, Bae JS, Choi EM, Kang WJ, Sakaguchi S, Vinay DS, Kwon BS. 4-1BB-de-pendent inhibition of immunosuppression by activated CD4+CD25+ T cells. J Leukoc Biol 2004;75:785-791.
107. Elpek KG, Yolcu ES, Franke DD, Lacelle C, Schabowsky RH, Shirwan H. Ex vivo expansion ofCD4+CD25+FoxP3+ Tregulatorycells based on synergybetween IL-2 and 4-1BB signaling. J Immunol 2007;179:7295-7304.
108. Zhang P, Gao F, Wang Q, Wang X, Zhu F, Ma C, Sun W, Zhang L. Agonistic anti-4-1BB antibody promotes the expansion of natural regulatory T cells while maintaining Foxp3 expression. Scand J Immunol 2007;66:435-440.
109. Malek TR, Yu A, Vincek V, Scibelli P, Kong L. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity2002;17:167-178.
110. Zheng XX, Sanchez-Fueyo A, Sho M, Domenig C, Sayegh MH, Strom TB. Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity 2003;19:503-514.
111. Nelson BH. IL-2, regulatory T cells, and tolerance. J Immunol. 2004;172:3983-3988.
112. Thornton AM, Donovan EE, Piccirillo CA, Shevach EM. Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol. 2004;172:6519-6523.
113. Shah MH, Freud AG, Benson DM Jr, Ferkitich AK, Dezube BJ, Bernstein ZP, Caligiuri MA. A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer. Clin Cancer Res 2006;12:3993-3996.
114. Zhang H, Chua KS, Guimond M, Kapoor V, Brown MV, Fleisher TA, Long LM, Bernstein D, Hill BJ, Douek DC, Berzofsky JA, Carter CS, Read EJ, Helman LJ, Mackall CL. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatoryT cells. Nat Med 2005;11:1238-1243.
115. Koenen HJ, Fasse E, Joosten I. IL-15 and cognate antigen successfully expand de novo-induced human antigen-specific regulatory CD4+ T cells that require antigen-specific activation for suppression. J Immunol 2003;171:6431-6441.
116. Karakhanova S, Munder M, Schneider M, Bonyhadi M, Ho AD, Goerner M. Highly efficient expansion of human CD4+CD25+ regulatory T cells for cellular immunotherapyin patients with graft-versus-host disease. J Immunother 2006;29:336-349.
117. Wolf D, Rumpold H, Koppelstätter C, Gastl GA, Steurer M, Mayer G, Gunsilius E, Tilg H, Wolf AM. Telomere length of in vivo expanded CD4(+)CD25 (+) regulatory T-cells is preserved in cancer patients. Cancer Immunol Immunother 2006; 55:1198-1208.
118. Strauss L, Whiteside TL, Knights A, Bergmann C, Knuth A, Zippelius A. Selective survival of naturally occurring human CD4+CD25+FoxP3+ regulatory T cells cultured with rapamycin. J Immunol 2007;178:320-329.
119. Keever-Taylor CA, Browning MB, Johnson BD, Truitt RL, Bredeson CN, Behn B, Tsao A. Rapamycin enriches for CD4(+) CD25(+) CD27(+) Foxp3(+) regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis. Cytotherapy 2007;9:144-57.
120. Ochando JC, Yopp AC, Yang Y, Garin A, Li Y, Boros P, Llodra J, Ding Y, Lira SA, Krieger NR, Bromberg JS. Lymph node occupancy is required for the peripheral development of alloantigen-specific FoxP3+ regulatory T cells. J Immunol 2005; 174:6993-7005.
121. Samy ET, Parker LA, Sharp CP, Tung KS. Continuous control of autoimmune disease by antigen-dependent polyclonal CD4+CD25+ regulatory T cells in the regional lymph node. J Exp Med 2005;202:771-781.
122. Neujahr DC, Chen C, Huang X, Markmann JF, Cobbold S, Waldmann H, Sayegh MH, Hancock WW, Turka LA. Accelerated memory cell homeostasis during T cell depletion and approaches to overcome it. J Immunol 2006;176:4632-4639.
123. Wan S, Xia C, Morel L. IL-6 produced by dendritic cells from lupus-prone mice inhibits CD4+CD25+ T cell regulatoryfunctions. J Immunol 2007;178:271-279.
124. Xu L, Kitani A, Fuss I, Strober W. Regulatory T cells induce CD4+CD25-Foxp3-T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-β. J Immunol 2007;178:6725-6729.
125. Crellin NK, Garcia RV, Levings MK. Flow cytometry-based methods for studying signaling in human CD4+CD25+FoxP3+ T regulatory cells. J Immunol Methods 2007;324:92-104.
126. Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, von Boehmer H. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol 2005;6:1219-1227.
127. Baron U, Floess S, Wieczorek G, Baumann K, Grutzkau A, Dong J, Thiel A, Boeld TJ, Hoffmann P, Edinger M, Türbachova I, Hamann A, Olek S, Huehn J. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur J Immunol 2007;37:2378-2389.
128. Polansky JK, Kretschmer K, Freyer J, Floess S, Garbe A, Baron U, Olek S, Hamann A, von Boehmer H, Huehn J. DNA methylation controls Foxp3 gene expression. Eur J Immunol 2008;38:1654-1663.
129. Floess S, Freyer J, Siewert C, Baron U, Olek S, Polansky J, Schlawe K, Chang HD, Bopp T, Schmitt E, Klein-Hessling S, Serfling E, Hamann A, Huehn J. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 2007;5:e38.
130. Fantini MC, Becker C, Tubbe I, Nikolaev A, Lehr HA, Galle P, Neurath MF. Transforming growth factor beta induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis. Gut 2006;55:671-680.
131. Rao PE, Petrone AL, Ponath PD. Differentiation and expansion of T cells with regulatory function from human peripheral lymphocytes by stimulation in the presence ofTGF-β.JImmunol2005;174:1446-1455.
132. Yamagiwa S, Gray JD, Hashimoto S, Horwitz DA. A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood. J Immunol 2001;166:7282-7289.
133. Battaglia M, Roncarolo MG. In vivo neutralization of inflammatory cytokines might not be necessary for regulatory T-cell immunotherapy. Nat Rev Immunol 2008;8. doi:10.1038/nri2138-c2.
134. Trenado A, Sudres M, Tang Q, Maury S, Charlotte F, Gregoire S, Bonyhadi M, Klatz- mann D, Salomon BL, Cohen JL. Ex vivo-expanded CD4+CD25+ immunoregulatoryTcellspreventgraft-versus-host-diseasebyinhibitingactivation/ differentiation of pathogenic T cells. J Immunol 2006;176:266-273.
135. Hayashi Y, Tsukumo S, Shiota H, Kishihara K, Yasutomo K. Antigen-specific T cell repertoire modification of CD4+CD25+ regulatory T cells. J Immunol 2004; 172:5240-5248.
136. Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J, Masteller EL, McDevitt H, Bonyhadi M, Bluestone JA. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 2004;199:1455-1465.
137. Trenado A, Charlotte F, Fisson S, Yagello M, Klatzmann D, Salomon BL, Cohen JL. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest 2003;112:1688-1696.
138. Jiang S, Camara N, Lombardi G, Lechler RI. Induction of allopeptide-specific human CD4+CD25+ regulatory T cells ex vivo. Blood 2003;102:2180-2186.
139. Battaglia M, Gregori S, Bacchetta R, Roncarolo MG. Tr1 cells: From discovery to their clinical application. Semin Immunol 2006;18:120-127.
140. Yamazaki S, Inaba K, Tarbell KV, Steinman RM. Dendritic cells expand antigen-specific FoxP3+ CD25+ CD4+ regulatory T cells including suppressors of alloreactivity. Immunol Rev2006;212:314-329.
141. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007;117:1147-1154.
142. Mellor AL, Baban B, Chandler P, Marshall B, Jhaver K, Hansen A, Koni PA, Iwa- shima M, Munn DH. Induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 2003;171:1652-1655.
143. Steinbrink K,Jonuleit H,Muller G,Schuler G,Knop J,Enk AH.IL10-treatedhuman dendritic cells induce a melanoma-antigen-specific anergy in CD8+ T cells resultingc in a failure to lyse tumorcells. Blood 1999;93:1634-1645.
144. Vigoroux S, Yvon E, Biagi E, Brenner MK. Antigen-induced regulatory T cells. Blood 2004;104:26-33.
145. SteinbrinkK,WolflM,JonuleitH, KnopJ, EnkAH. InductionoftolerancebyIL10- treated dendritic cells. J Immunol 1997;159:4772-4782.
146. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of IL10-producing, nonproliferating CD4+ T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000;192:183-191.
147. Li L, Li SP, Min J, Zheng L. Hepatoma cells inhibit the differentiation and maturation of dendritic cells and increase the production of regulatory T cells. Immunol Lett 2007;114:38-45.
148. Bayry J, Triebel F, Kaveri SV, Tough DF. Human dendritic cells acquire a semimature phenotype and lymph node homing potential through interaction with CD4+CD25+ regulatory T cells. J Immunol 2007;178:4184-4193.
149. Encabo A, Solves P, Carbonell-Uberos F, Minana MD. The functional immaturity of dendritic cells can be relevant to increased tolerance associated with cord blood transplantation. Transfusion 2007;47:272-279.
150. Levings MK, Gregori S, Tresoldi E, Cazzaniga S, Bonini C, Roncarolo MG. Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Trcells. Blood 2005;105:1162-1169.
151. Misra N, Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Cutting edge: Human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 2004;172:4676-4680.
152. Mellor AL, Chandler P, Baban B, Hansen AM, Marshall B, Pihkala J, Waldmann H, Cobbold S, Adams E, Munn DH. Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated
153. Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, Messina JL, Chandler P, Koni PA, Mellor AL. Expression ofindoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004;114:280-290.
154. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat RevImmunol2007;7:610-621.
155. Sawitzki B,Kingsley CI,Oliveira V,Karim M,Herber M,Wood KJ.IFN-gammaproduction by alloantigen-reactive regulatory T cells is important for their regulatory function in vivo. J Exp Med 2005;201:1925-1935.
156. Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, Azuma M, Blazar BR, Mellor AL, Munn DH. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 2007;117:2570-2582.
157. Munn DH, Sharma MD, Mellor AL. Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol 2004; 172:4100-4110.
158. Hill M, Tanguy-Royer S, Royer P, Chauveau C, Asghar K, Tesson L, Lavainne F, Remy S, Brion R, Hubert FX, Heslan M, Rimbert M, Berthelot L, Moffett JR, Josien R, Gregoire M, Anegon I. IDO expands human CD4+CD25high regulatory T cells by promoting maturation of LPS-treated dendritic cells. Eur J Immunol 2007; 37:3054-3062.
159. Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB, Marshall B, Chandler P, Antonia SJ, Burgess R, Slingluff CL Jr, Mellor AL. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002;297:1867-1870.
160. Hong J, Gong ZJ. Human plasmacytoid dendritic cells from patients with chronic hepatitis B virus infection induce the generation of a higher proportion of CD4(+) and CD25(+) regulatory T cells compared with healthy patients. Hepatol Res 2008;38:362-373.
161. Banerjee DK, Dhodapkar MV, Matayeva E, Steinman RM, Dhodapkar KM. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 2006;108:2655-2661.
162. Moreau A, Chiffoleau E, Beriou G, Deschamps JY, Heslan M, Ashton-Chess J, RollingF, Josien R, MoullierP, CuturiMC, Alliot-Licht B. Superiorityofbonemarrow- derived dendritic cells over monocyte-derived ones for the expansion of regulatory T cells in the macaque. Transplantation 2008;85:1351-1356.
163. Larmonier N, Marron M, Zeng Y, Cantrell J, Romanoski A, Sepassi M, Thompson S, Chen X, Andreansky S, Katsanis E. Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol Immunother 2007;56:48-59.
164. Houot R, Perrot I, Garcia E, Durand I, Lebecque S. Human CD4+CD25high regulatory T cells modulate myeloid but not plasmacytoid dendritic cells activation. J Immunol 2006;176:5293-5298.
165. Mahnke K, Qian Y, Knop J, Enk AH. Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells. Blood 2003;101:4862-4869.
166. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+T cell tolerance. J Exp Med 2002;196:1627-1638.
167. Bruder D, Westendorf AM, Hansen W, Prettin S, Gruber AD, Qian Y, von Boehmer H, Mahnke K, Buer J. On the edge ofautoimmunity: T-cell stimulation bysteady- state dendritic cells prevents autoimmune diabetes. Diabetes 2005;54:3395-3401.
168. Jiang S, Tsang J, Game DS, Stevenson S, Lombardi G, Lechler RI. Generation and expansion of human CD4+ CD25+ regulatory T cells with indirect allospecificity: Potential reagents to promote donor-specific transplantation tolerance. Transplantation 2006;82:1738-1743.
169. Golshayan D, Jiang S, Tsang J, Garin MI, Mottet C, Lechler RI. In vitro-expanded donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance. Blood 2007;109:827-835.
170. Asiedu CK, Goodwin KJ, Balgansuren G, Jenkins SM, Le Bas-Bernardet S, Jargal U, Neville DM Jr, Thomas JM. Elevated Tregulatory cells in long-termstable transplant tolerance in rhesus macaques induced by anti-CD3 immunotoxin and deoxyspergualin. J Immunol 2005;175:8060-8068.
171. Jiang S, Golshayan D, Tsang J, Lombardi G, Lechler RI. In vitro expanded alloantigen-specific CD4+CD25+ regulatory T cell treatment for the induction of donor- specific transplantation tolerance. Int Immunopharmacol 2005;6:1879-1882.
172. George TC, Bilsborough J, Viney JL, Norment AM. High antigen dose and activated dendritic cells enable Th cells to escape regulatory T cell-mediated suppression in vitro. EurJ Immunol2003;33:502-511.
173. Godfrey WR, Spoden DJ, Ge YG, Baker SR, Liu B, Levine BL, June CH, Blazar BR, Porter SB. Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood 2005;105:750-758.
174. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002;196:389-399.
175. Qin S, Cobbold SP, Pope H, Elliott J, Kioussis D, Davies J, Waldmann H. "Infectious" transplantation tolerance. Science 1993;259:974-977.
176. Anastasi E, Campese AF, Bellavia D, Bulotta A, Balestri A, Pascucci M, Checquolo S, Gradini R, Lendahl U, Frati L, Gulino A, Di Mario U, Screpanti I. Expression of activated Notch3 in transgenic mice enhances generation of T regulatory cells and protects against experimental autoimmune diabetes. J Immunol 2003;171:4504-4511.
177. Ostroukhova M, Qi Z, Oriss TB, Dixon-McCarthy B, Ray P, Ray A. Treg-mediated immunosuppression involves activation of the Notch-HES1 axis by membrane-bound TGF-beta. J Clin Invest 2006;116:996-1004.
178. Samon JB, Champhekar A, Minter LM, Telfer JC, Miele L, Fauq A, Das P, Golde TE, Osborne BA. Notch1 and TGF/ 1 cooperatively regulate Foxp3 expression and the maintenance of peripheral regulatory T cells. Blood 2008;112:1813-1821.
179. Chen ZM, O'Shaughnessy MJ, Gramaglia I, Panoskaltsis-Mortari A, Murphy WJ, Narula S, Roncarolo MG, Blazar BR. IL-10 and TGF-beta induce alloreactive CD4+CD25- T cells to acquire regulatory cell function. Blood 2001;101:5076-5083.
180. Dhodapkar MV, Steinman RM, KrasovskyJ, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001;193:233-238.
181. Moseman EA, Liang X, Dawson AJ, Panoskaltsis-Mortari A, Krieg AM, Liu YJ, Blazar BR, Chen W. Human plasmacytoid dendritic cells activated by CpG oligodeoxy- nucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol 2004;173:4433-4442.
182. Barrat FJ, Cua DJ, Boonstra A, Richards DF, Crain C, Savelkoul HF, de Waal-Malefyt R, Coffman RL, Hawrylowicz CM, O'Garra A. In vitro generation of interleukin 10- producing regulatory CD4+ T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 2002; 195:603-616.
183. Maccario R, Podesta M, Moretta A, Cometa A, Comoli P, Montagna D, Daudt L, Ibatici A, Piaggio G, Pozzi S, Frassoni F, Locatelli F. Interaction of human mesenchy- mal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phe- notype. Haematologica 2005;90:516-525.
184. Tian Y, Deng YB, Huang YJ, Wang Y. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation. Immunol Invest 2008;37:29-42.
185. Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L, Borg C, Saas P, Tiberghien P, Rouas-Freiss N, Carosella ED, Deschaseaux F. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFoxP3+ regulatory T cells. Stem Cells 2008;26:212-222.
186. Grundstrom S, Cederbom L, Sundstedt A, Scheipers P, Ivars F. Superantigen- induced regulatory T cells display different suppressive functions in the presence or absence of natural CD4+CD25+ regulatory T cells in vivo. J Immunol 2003;170:5008-5017.
187. Tang W, Yang Y, Zhang F, Li YC, Zhou R, Wang JX, Zhu YN, Li XY, Yang YF, Zuo JP. Prevention of graft-versus-host disease by a novel immunosuppressant, (5R)-5- hydroxytriptolide (LLDT-8), through expansion of regulatory T cells. Int Immunopharmacol2005;5:1904-1913.
188. Liu Y, Chen Y, Liu FQ, Lamb JR, Tam PK. Combined treatment with triptolide and rapamycin prolongs graft survival in a mouse model of cardiac transplantation. Transpl Int 2008;21:483-494.
189. Waldmann H. Special regulatory T cell review: The suppression problem! Immunology 2008;123:11-12.
190. Wadman M. London's disastrous drug trial has serious side effects for research. Nature 2006;440:388-389.
191. June CH, Blazar BR. Clinical application of expanded CD4+25+ cells. Semin Immunol 2006;18:78-88.